HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Long-term anti-proteinuric effect of Losartan in renal transplant recipients treated for hypertension.

AbstractBACKGROUND:
Hypertension is common after renal transplantation. Angiotensin II type 1 receptor antagonists are a new class of agents that, without the side-effects mediated by kinins, have shown their efficacy in the treatment of hypertension and heart failure. The aim of the study was to assess the efficacy and safety of Losartan for the treatment of hypertension and to evaluate its long-term effect on graft function in a group of stable renal transplant patients.
METHODS:
Eighteen non-diabetic renal transplant recipients evaluated at our unit for more than 1 year after transplantation (13-155 months) were enrolled. Losartan was administered for a period of 14. 2+/-6.86 (6-28) months at a dose of 25-100 mg/day depending on the antihypertensive response obtained.
RESULTS:
Losartan satisfactorily lowered systemic blood pressure. Overall graft function remained stable and a significant reduction in proteinuria was observed throughout the period on Losartan (1.0+/-0.87 vs 0.4+/-0.83 g/l, P=0. 003). No serious side-effects were reported except for a significant reduction in the mean haemoglobin concentration (from 13.5+/-1.74 g/dl to 12.2+/-2.19 g/dl; P=0.001).
CONCLUSIONS:
A satisfactory antihypertensive effect was observed with long-term therapy with Losartan. A significant reduction in proteinuria without adversely affecting graft function was the main beneficial effect observed. Losartan was generally well tolerated and a decrease in haemoglobin was the major side-effect.
AuthorsJ Calviño, X M Lens, R Romero, D Sánchez-Guisande
JournalNephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (Nephrol Dial Transplant) Vol. 15 Issue 1 Pg. 82-6 (Jan 2000) ISSN: 0931-0509 [Print] England
PMID10607772 (Publication Type: Journal Article)
Chemical References
  • Angiotensin Receptor Antagonists
  • Antihypertensive Agents
  • Hemoglobins
  • Receptor, Angiotensin, Type 1
  • Receptor, Angiotensin, Type 2
  • Losartan
Topics
  • Adult
  • Aged
  • Angiotensin Receptor Antagonists
  • Antihypertensive Agents (adverse effects, therapeutic use)
  • Blood Pressure (drug effects)
  • Female
  • Hemoglobins (metabolism)
  • Humans
  • Hypertension (drug therapy, etiology, physiopathology)
  • Kidney Transplantation (adverse effects, physiology)
  • Losartan (adverse effects, therapeutic use)
  • Male
  • Middle Aged
  • Proteinuria (drug therapy)
  • Receptor, Angiotensin, Type 1
  • Receptor, Angiotensin, Type 2

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: